Site search
2831 results for '' found
[NHL37] An open-label, single-arm, phase 2 trial of GlOfitamab anD pIrtobrutinib [LOXo-305] in patients with mantle cell lymphoma and prior exposure to a BTK inhibitor – GOlDiLOX (NCT05833763)
[NHL37] An open-label, single-arm, phase 2 trial of GlOfitamab anD pIrtobrutinib [LOXo-305] in patients with mantle cell lymphoma and prior exposure to a BTK inhibitor – GOlDiLOX (NCT05833763)
/
Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precurs
Phase 3 Randomized, Controlled Study of Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precurs
/
A PHASE Ib, OPEN-LABEL, MULTICENTER DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF XmAb24306 IN COMBINATION WITH CEVOSTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY M
A PHASE Ib, OPEN-LABEL, MULTICENTER DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF XmAb24306 IN COMBINATION WITH CEVOSTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY M
/
AN OPEN-LABEL, MULTICENTER, PHASE Ib TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF THE COMBINATION OF CEVOSTAMAB AND ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE
AN OPEN-LABEL, MULTICENTER, PHASE Ib TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF THE COMBINATION OF CEVOSTAMAB AND ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE
/
A Phase 1b, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple M
A Phase 1b, Open-Label, Multicenter, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of XMAB24306 in Combination with Daratumumab in Patients with Relapsed/Refractory Multiple M
/
AN OPEN-LABEL, MULTICENTER, PHASE Ib TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF CEVOSTAMAB AS MONOTHERAPY AND CEVOSTAMAB PLUS POMALIDOMIDE AND DEXAMETHASONE OR CEVOSTAMAB PLU
AN OPEN-LABEL, MULTICENTER, PHASE Ib TRIAL EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF CEVOSTAMAB AS MONOTHERAPY AND CEVOSTAMAB PLUS POMALIDOMIDE AND DEXAMETHASONE OR CEVOSTAMAB PLU
/
A PHASE Ia/Ib DOSE-ESCALATION AND DOSE EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN P
A PHASE Ia/Ib DOSE-ESCALATION AND DOSE EXPANSION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS, AND ACTIVITY OF GDC-6036 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-CANCER THERAPIES IN P
/
A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF BLYG8824A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC COLORECTA
A PHASE I, OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF BLYG8824A ADMINISTERED INTRAVENOUSLY AS A SINGLE AGENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC COLORECTA
/
An open-label, non-randomized, single-arm pilot study to evaluate the safety and efficacy of multiple pulsed focused ultrasound treatment in patients with drug resistant temporal lobe epilepsy (N
An open-label, non-randomized, single-arm pilot study to evaluate the safety and efficacy of multiple pulsed focused ultrasound treatment in patients with drug resistant temporal lobe epilepsy (N
/
Genotype-Phenotype correlations in Multiple Sclerosis (MS) and Neuromyelitis Optica Spectrum Disorder (NMOSD) (Trial Not Registered)
Genotype-Phenotype correlations in Multiple Sclerosis (MS) and Neuromyelitis Optica Spectrum Disorder (NMOSD) (Trial Not Registered)
/